<DOC>
	<DOCNO>NCT02612454</DOCNO>
	<brief_summary>The primary objective study ass long-term safety dupilumab pediatric patient AD . The secondary objective study : - To assess long-term efficacy dupilumab pediatric patient AD - To assess trough concentration functional dupilumab serum immunogenicity pediatric patient AD re-treatment dupilumab .</brief_summary>
	<brief_title>A Study Assess Long-term Safety Dupilumab ( REGN668/SAR231893 ) Administered Patients 6 &lt; 18 Year Age With Atopic Dermatitis ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Key 1 . Male female , â‰¥6 &lt; 18 year age time screen 2 . Participated prior dupilumab study pediatric patient AD adequately complete visit assessment require treatment followup period , define prior study protocol Key 1 . Patients , participation prior dupilumab study pediatric patient AD , develop serious adverse event ( SAE ) potentially relate study drug adverse event ( AE ) lead permanent study drug discontinuation prior dupilumab study , except AE worsen AD , patient receive placebo ( know ) 2 . Patients , participation prior dupilumab study pediatric patient AD , develop AE deem related dupilumab lead study treatment discontinuation , opinion investigator medical monitor could indicate continue treatment dupilumab may present unreasonable risk patient 3 . Treatment investigational drug , dupilumab , within 8 week within 5 halflives ( know ) , whichever longer , baseline visit 4 . History human immunodeficiency virus ( HIV ) infection 5 . Known suspected immunosuppression 6 . Recent infection require antiinfectious treatment 7 . Recent history high risk clinical endoparasitoses 8 . High risk population ( low life expectancy , severe concomitant disease , etc . ) 9 . Pregnant breastfeed woman 10 . Patients reproductive potential sexually active unwilling use adequate contraception 11 . Treatment live ( attenuate ) vaccine within 12 week baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Eczema</keyword>
</DOC>